Clinical utility of C‐terminal telopeptide of type 1 collagen in multiple myeloma
Summary Myeloma bone disease (MBD) is a major cause of morbidity in multiple myeloma (MM). We investigated bone turnover markers (BTM) as relapse predictors and biomarkers for monitoring MBD. We measured C‐terminal telopeptide of type I collagen (CTX‐1), and Procollagen type 1 N Propeptide (P1NP) in...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2016-04, Vol.173 (1), p.82-88 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 88 |
|---|---|
| container_issue | 1 |
| container_start_page | 82 |
| container_title | British journal of haematology |
| container_volume | 173 |
| creator | Ting, Kay R. Brady, Jennifer J. Hameed, Abdul Le, Giao Meiller, Justine Verburgh, Estelle Bayers, Christopher Benjamin, Dalia Anderson, Kenneth C. Richardson, Paul G. Dowling, Paul Clynes, Martin Fitzgibbon, Maria C. O'Gorman, Peter |
| description | Summary
Myeloma bone disease (MBD) is a major cause of morbidity in multiple myeloma (MM). We investigated bone turnover markers (BTM) as relapse predictors and biomarkers for monitoring MBD. We measured C‐terminal telopeptide of type I collagen (CTX‐1), and Procollagen type 1 N Propeptide (P1NP) in 86 MM patients and 26 controls. CTX‐1 was higher in newly diagnosed patients compared to control, remission and relapse (P |
| doi_str_mv | 10.1111/bjh.13928 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1785243259</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1785243259</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3938-41eb4b9b5fac0927c309607c105c08abb1dddc61f958d97a297fcbfa173fc6393</originalsourceid><addsrcrecordid>eNqNkLtOwzAUQC0EoqUw8AMoIwwpvnESxyNEQEGVGIDZsh0HXDkPEkcoG5_AN_IluLSwIeHlSr5HR1cHoWPAc_DvXK5e5kBYlO2gKZA0CSOIYRdNMcY0BBxnE3TQ9yuMgeAE9tEkSmlGYyBT9JBbUxslbDA4Y40bg6YM8s_3D6e7ytT-32nbtLp1ptDrnRtbHUCgGmvFs64DUwfVYJ1prQ6q0bOVOER7pbC9PtrOGXq6vnrMF-Hy_uY2v1iGijCShTFoGUsmk1IozCKqCGYppgpwonAmpISiKFQKJUuyglERMVoqWQqgpFSpV8zQ6cbbds3roHvHK9Mr7Q-rdTP0HGiWRDGJkv-gNE0J9tk8erZBVdf0fadL3namEt3IAfN1bu5z8-_cnj3ZagdZ6eKX_OnrgfMN8GasHv828cu7xUb5Bcy6ieM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776630141</pqid></control><display><type>article</type><title>Clinical utility of C‐terminal telopeptide of type 1 collagen in multiple myeloma</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ting, Kay R. ; Brady, Jennifer J. ; Hameed, Abdul ; Le, Giao ; Meiller, Justine ; Verburgh, Estelle ; Bayers, Christopher ; Benjamin, Dalia ; Anderson, Kenneth C. ; Richardson, Paul G. ; Dowling, Paul ; Clynes, Martin ; Fitzgibbon, Maria C. ; O'Gorman, Peter</creator><creatorcontrib>Ting, Kay R. ; Brady, Jennifer J. ; Hameed, Abdul ; Le, Giao ; Meiller, Justine ; Verburgh, Estelle ; Bayers, Christopher ; Benjamin, Dalia ; Anderson, Kenneth C. ; Richardson, Paul G. ; Dowling, Paul ; Clynes, Martin ; Fitzgibbon, Maria C. ; O'Gorman, Peter</creatorcontrib><description>Summary
Myeloma bone disease (MBD) is a major cause of morbidity in multiple myeloma (MM). We investigated bone turnover markers (BTM) as relapse predictors and biomarkers for monitoring MBD. We measured C‐terminal telopeptide of type I collagen (CTX‐1), and Procollagen type 1 N Propeptide (P1NP) in 86 MM patients and 26 controls. CTX‐1 was higher in newly diagnosed patients compared to control, remission and relapse (P < 0·05), and decreased following treatment. In the setting of relapse, a CTX‐1 rise greater than the calculated least significant change (LSC) was observed in 26% of patients 3–6 months prior to relapse (P = 0·007), and in 60·8% up to 3 months before relapse (P = 0·015). Statistically significant changes in CTX‐1 levels were also observed in patients who were with and without bisphosphonate therapy at the time of relapse. In patients with normal renal function, mean CTX‐1 level was highest in the newly diagnosed group (0·771 ± 0·400 μg/l), and lowest in the remission group (0·099 ± 0·070 μg/l) (P < 0·0001). P1NP levels were not statistically different across the patient groups. We conclude that CTX‐1, measured on an automated hospital laboratory platform, has a role in routine treatment monitoring and predicting relapse of MBD, even in patients on bisphosphonates.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.13928</identifier><identifier>PMID: 26787413</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Bone Diseases - blood ; Bone Diseases - drug therapy ; bone markers ; bone resorption ; Collagen Type I - blood ; CTX‐1 ; Female ; Humans ; Male ; Middle Aged ; multiple myeloma ; Multiple Myeloma - blood ; Multiple Myeloma - drug therapy ; myeloma bone disease ; Neoplasm Proteins - blood ; Peptide Fragments - blood ; Procollagen - blood</subject><ispartof>British journal of haematology, 2016-04, Vol.173 (1), p.82-88</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3938-41eb4b9b5fac0927c309607c105c08abb1dddc61f958d97a297fcbfa173fc6393</citedby><cites>FETCH-LOGICAL-c3938-41eb4b9b5fac0927c309607c105c08abb1dddc61f958d97a297fcbfa173fc6393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.13928$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.13928$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26787413$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ting, Kay R.</creatorcontrib><creatorcontrib>Brady, Jennifer J.</creatorcontrib><creatorcontrib>Hameed, Abdul</creatorcontrib><creatorcontrib>Le, Giao</creatorcontrib><creatorcontrib>Meiller, Justine</creatorcontrib><creatorcontrib>Verburgh, Estelle</creatorcontrib><creatorcontrib>Bayers, Christopher</creatorcontrib><creatorcontrib>Benjamin, Dalia</creatorcontrib><creatorcontrib>Anderson, Kenneth C.</creatorcontrib><creatorcontrib>Richardson, Paul G.</creatorcontrib><creatorcontrib>Dowling, Paul</creatorcontrib><creatorcontrib>Clynes, Martin</creatorcontrib><creatorcontrib>Fitzgibbon, Maria C.</creatorcontrib><creatorcontrib>O'Gorman, Peter</creatorcontrib><title>Clinical utility of C‐terminal telopeptide of type 1 collagen in multiple myeloma</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
Myeloma bone disease (MBD) is a major cause of morbidity in multiple myeloma (MM). We investigated bone turnover markers (BTM) as relapse predictors and biomarkers for monitoring MBD. We measured C‐terminal telopeptide of type I collagen (CTX‐1), and Procollagen type 1 N Propeptide (P1NP) in 86 MM patients and 26 controls. CTX‐1 was higher in newly diagnosed patients compared to control, remission and relapse (P < 0·05), and decreased following treatment. In the setting of relapse, a CTX‐1 rise greater than the calculated least significant change (LSC) was observed in 26% of patients 3–6 months prior to relapse (P = 0·007), and in 60·8% up to 3 months before relapse (P = 0·015). Statistically significant changes in CTX‐1 levels were also observed in patients who were with and without bisphosphonate therapy at the time of relapse. In patients with normal renal function, mean CTX‐1 level was highest in the newly diagnosed group (0·771 ± 0·400 μg/l), and lowest in the remission group (0·099 ± 0·070 μg/l) (P < 0·0001). P1NP levels were not statistically different across the patient groups. We conclude that CTX‐1, measured on an automated hospital laboratory platform, has a role in routine treatment monitoring and predicting relapse of MBD, even in patients on bisphosphonates.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bone Diseases - blood</subject><subject>Bone Diseases - drug therapy</subject><subject>bone markers</subject><subject>bone resorption</subject><subject>Collagen Type I - blood</subject><subject>CTX‐1</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multiple myeloma</subject><subject>Multiple Myeloma - blood</subject><subject>Multiple Myeloma - drug therapy</subject><subject>myeloma bone disease</subject><subject>Neoplasm Proteins - blood</subject><subject>Peptide Fragments - blood</subject><subject>Procollagen - blood</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkLtOwzAUQC0EoqUw8AMoIwwpvnESxyNEQEGVGIDZsh0HXDkPEkcoG5_AN_IluLSwIeHlSr5HR1cHoWPAc_DvXK5e5kBYlO2gKZA0CSOIYRdNMcY0BBxnE3TQ9yuMgeAE9tEkSmlGYyBT9JBbUxslbDA4Y40bg6YM8s_3D6e7ytT-32nbtLp1ptDrnRtbHUCgGmvFs64DUwfVYJ1prQ6q0bOVOER7pbC9PtrOGXq6vnrMF-Hy_uY2v1iGijCShTFoGUsmk1IozCKqCGYppgpwonAmpISiKFQKJUuyglERMVoqWQqgpFSpV8zQ6cbbds3roHvHK9Mr7Q-rdTP0HGiWRDGJkv-gNE0J9tk8erZBVdf0fadL3namEt3IAfN1bu5z8-_cnj3ZagdZ6eKX_OnrgfMN8GasHv828cu7xUb5Bcy6ieM</recordid><startdate>201604</startdate><enddate>201604</enddate><creator>Ting, Kay R.</creator><creator>Brady, Jennifer J.</creator><creator>Hameed, Abdul</creator><creator>Le, Giao</creator><creator>Meiller, Justine</creator><creator>Verburgh, Estelle</creator><creator>Bayers, Christopher</creator><creator>Benjamin, Dalia</creator><creator>Anderson, Kenneth C.</creator><creator>Richardson, Paul G.</creator><creator>Dowling, Paul</creator><creator>Clynes, Martin</creator><creator>Fitzgibbon, Maria C.</creator><creator>O'Gorman, Peter</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201604</creationdate><title>Clinical utility of C‐terminal telopeptide of type 1 collagen in multiple myeloma</title><author>Ting, Kay R. ; Brady, Jennifer J. ; Hameed, Abdul ; Le, Giao ; Meiller, Justine ; Verburgh, Estelle ; Bayers, Christopher ; Benjamin, Dalia ; Anderson, Kenneth C. ; Richardson, Paul G. ; Dowling, Paul ; Clynes, Martin ; Fitzgibbon, Maria C. ; O'Gorman, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3938-41eb4b9b5fac0927c309607c105c08abb1dddc61f958d97a297fcbfa173fc6393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bone Diseases - blood</topic><topic>Bone Diseases - drug therapy</topic><topic>bone markers</topic><topic>bone resorption</topic><topic>Collagen Type I - blood</topic><topic>CTX‐1</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multiple myeloma</topic><topic>Multiple Myeloma - blood</topic><topic>Multiple Myeloma - drug therapy</topic><topic>myeloma bone disease</topic><topic>Neoplasm Proteins - blood</topic><topic>Peptide Fragments - blood</topic><topic>Procollagen - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ting, Kay R.</creatorcontrib><creatorcontrib>Brady, Jennifer J.</creatorcontrib><creatorcontrib>Hameed, Abdul</creatorcontrib><creatorcontrib>Le, Giao</creatorcontrib><creatorcontrib>Meiller, Justine</creatorcontrib><creatorcontrib>Verburgh, Estelle</creatorcontrib><creatorcontrib>Bayers, Christopher</creatorcontrib><creatorcontrib>Benjamin, Dalia</creatorcontrib><creatorcontrib>Anderson, Kenneth C.</creatorcontrib><creatorcontrib>Richardson, Paul G.</creatorcontrib><creatorcontrib>Dowling, Paul</creatorcontrib><creatorcontrib>Clynes, Martin</creatorcontrib><creatorcontrib>Fitzgibbon, Maria C.</creatorcontrib><creatorcontrib>O'Gorman, Peter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ting, Kay R.</au><au>Brady, Jennifer J.</au><au>Hameed, Abdul</au><au>Le, Giao</au><au>Meiller, Justine</au><au>Verburgh, Estelle</au><au>Bayers, Christopher</au><au>Benjamin, Dalia</au><au>Anderson, Kenneth C.</au><au>Richardson, Paul G.</au><au>Dowling, Paul</au><au>Clynes, Martin</au><au>Fitzgibbon, Maria C.</au><au>O'Gorman, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical utility of C‐terminal telopeptide of type 1 collagen in multiple myeloma</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2016-04</date><risdate>2016</risdate><volume>173</volume><issue>1</issue><spage>82</spage><epage>88</epage><pages>82-88</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
Myeloma bone disease (MBD) is a major cause of morbidity in multiple myeloma (MM). We investigated bone turnover markers (BTM) as relapse predictors and biomarkers for monitoring MBD. We measured C‐terminal telopeptide of type I collagen (CTX‐1), and Procollagen type 1 N Propeptide (P1NP) in 86 MM patients and 26 controls. CTX‐1 was higher in newly diagnosed patients compared to control, remission and relapse (P < 0·05), and decreased following treatment. In the setting of relapse, a CTX‐1 rise greater than the calculated least significant change (LSC) was observed in 26% of patients 3–6 months prior to relapse (P = 0·007), and in 60·8% up to 3 months before relapse (P = 0·015). Statistically significant changes in CTX‐1 levels were also observed in patients who were with and without bisphosphonate therapy at the time of relapse. In patients with normal renal function, mean CTX‐1 level was highest in the newly diagnosed group (0·771 ± 0·400 μg/l), and lowest in the remission group (0·099 ± 0·070 μg/l) (P < 0·0001). P1NP levels were not statistically different across the patient groups. We conclude that CTX‐1, measured on an automated hospital laboratory platform, has a role in routine treatment monitoring and predicting relapse of MBD, even in patients on bisphosphonates.</abstract><cop>England</cop><pmid>26787413</pmid><doi>10.1111/bjh.13928</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2016-04, Vol.173 (1), p.82-88 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1785243259 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Aged, 80 and over Bone Diseases - blood Bone Diseases - drug therapy bone markers bone resorption Collagen Type I - blood CTX‐1 Female Humans Male Middle Aged multiple myeloma Multiple Myeloma - blood Multiple Myeloma - drug therapy myeloma bone disease Neoplasm Proteins - blood Peptide Fragments - blood Procollagen - blood |
| title | Clinical utility of C‐terminal telopeptide of type 1 collagen in multiple myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T03%3A10%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20utility%20of%20C%E2%80%90terminal%20telopeptide%20of%20type%201%20collagen%20in%20multiple%20myeloma&rft.jtitle=British%20journal%20of%20haematology&rft.au=Ting,%20Kay%20R.&rft.date=2016-04&rft.volume=173&rft.issue=1&rft.spage=82&rft.epage=88&rft.pages=82-88&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.13928&rft_dat=%3Cproquest_cross%3E1785243259%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1776630141&rft_id=info:pmid/26787413&rfr_iscdi=true |